Fosinopril - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)Transporters (2)

Targets (1)Transporters (2)Biointeractions (3)

Identification

Name

Fosinopril

Accession Number

DB00492 (APRD00526)

Type

Small Molecule

Groups

Approved

Description

Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Structure

MOL SDF PDB SMILES InChI

Synonyms

(2S,4S)-4-Cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid

(2S,4S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid

(S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid

Fosinopril

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Fosinopril Sodium	NW2RTH6T2N	88889-14-9	TVTJZMHAIQQZTL-HREVRLCXSA-M	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ava-fosinopril	Tablet	10 mg	Oral	Avanstra Inc	2011-11-28	2014-08-21	Canada
Ava-fosinopril	Tablet	20 mg	Oral	Avanstra Inc	2011-11-28	2014-08-21	Canada
Fosinopril	Tablet	10 mg	Oral	Sanis Health Inc	2017-04-11	Not applicable	Canada
Fosinopril	Tablet	20 mg	Oral	Sanis Health Inc	2017-04-11	Not applicable	Canada
Fosinopril Tablets	Tablet	10 mg	Oral	Ranbaxy Inc.	Not applicable	Not applicable	Canada
Fosinopril Tablets	Tablet	20 mg	Oral	Ranbaxy Inc.	Not applicable	Not applicable	Canada
Fosinopril-10	Tablet	10 mg	Oral	Pro Doc Limitee	2008-10-23	Not applicable	Canada
Fosinopril-20	Tablet	20 mg	Oral	Pro Doc Limitee	2008-10-23	Not applicable	Canada
Jamp-fosinopril	Tablet	20 mg	Oral	Jamp Pharma Corporation	2010-05-17	Not applicable	Canada
Jamp-fosinopril	Tablet	10 mg	Oral	Jamp Pharma Corporation	2010-05-17	Not applicable	Canada
Lin-fosinopril	Tablet	10 mg	Oral	Linson Pharma Co.	2004-03-30	2008-07-16	Canada
Lin-fosinopril	Tablet	20 mg	Oral	Linson Pharma Co.	2004-03-30	2008-07-16	Canada
Monopril Tab 10mg	Tablet	10 mg	Oral	Bristol Myers Squibb	1992-12-31	2013-06-17	Canada
Monopril Tab 20mg	Tablet	20 mg	Oral	Bristol Myers Squibb	1992-12-31	2013-06-17	Canada
Mylan-fosinopril	Tablet	20 mg	Oral	Mylan Pharmaceuticals	2004-12-21	Not applicable	Canada
Mylan-fosinopril	Tablet	10 mg	Oral	Mylan Pharmaceuticals	2004-12-21	Not applicable	Canada
Nu-fosinopril	Tablet	10 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
Nu-fosinopril	Tablet	20 mg	Oral	Nu Pharm Inc	Not applicable	Not applicable	Canada
PHL-fosinopril	Tablet	10 mg	Oral	Pharmel Inc	Not applicable	Not applicable	Canada
PHL-fosinopril	Tablet	20 mg	Oral	Pharmel Inc	Not applicable	Not applicable	Canada
PMS-fosinopril	Tablet	10 mg	Oral	Pharmascience Inc	2005-02-08	Not applicable	Canada
PMS-fosinopril	Tablet	20 mg	Oral	Pharmascience Inc	2005-02-08	Not applicable	Canada
Ran-fosinopril	Tablet	10 mg	Oral	Ranbaxy Inc.	2007-08-15	Not applicable	Canada
Ran-fosinopril	Tablet	20 mg	Oral	Ranbaxy Inc.	2007-08-15	Not applicable	Canada
Ratio Fosinopril	Tablet	10 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2006-02-08	2008-08-01	Canada
Ratio Fosinopril	Tablet	20 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2006-02-08	2008-08-01	Canada
Riva-fosinopril	Tablet	10 mg	Oral	Laboratoire Riva Inc	2005-06-29	2016-05-31	Canada
Riva-fosinopril	Tablet	20 mg	Oral	Laboratoire Riva Inc	2005-06-29	2016-05-31	Canada
Teva-fosinopril	Tablet	10 mg	Oral	Teva	2003-12-05	Not applicable	Canada
Teva-fosinopril	Tablet	20 mg	Oral	Teva	2003-12-05	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-fosinopril	Tablet	10 mg	Oral	Apotex Corporation	2005-04-27	Not applicable	Canada
Apo-fosinopril	Tablet	20 mg	Oral	Apotex Corporation	2005-04-27	Not applicable	Canada
Fosinopril Na	Tablet	10 mg/1	Oral	Apotex Corporation	2005-05-18	2017-02-24	US
Fosinopril Na	Tablet	20 mg/1	Oral	Apotex Corporation	2005-05-18	2017-02-24	US
Fosinopril Na	Tablet	40 mg/1	Oral	Apotex Corporation	2005-05-18	2017-02-24	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	Exelan Pharmaceuticals, Inc.	2005-06-21	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Unit Dose Services	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Teva	2003-12-01	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Golden State Medical Supply	2011-12-27	Not applicable	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	A S Medication Solutions	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	40 1/1	Oral	A S Medication Solutions	2016-06-16	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Golden State Medical Supply	2011-12-27	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Remedy Repack	2016-01-04	2017-04-14	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	Camber Pharmaceuticals	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Exelan Pharmaceuticals, Inc.	2005-06-21	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Unit Dose Services	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Teva	2003-12-01	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	A S Medication Solutions	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	Aidarex Pharmaceuticals LLC	2005-06-21	Not applicable	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	Aurobindo Pharma	2011-03-30	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Camber Pharmaceuticals	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Exelan Pharmaceuticals, Inc.	2005-06-21	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Physicians Total Care, Inc.	2004-04-27	Not applicable	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	Eon Labs, Inc.	2004-04-23	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Eon Labs, Inc.	2004-04-23	Not applicable	US
Fosinopril Sodium	Tablet	10 1/1	Oral	Cipla Limited	2016-06-16	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Aidarex Pharmaceuticals LLC	2005-06-21	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Aurobindo Pharma	2011-03-30	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Camber Pharmaceuticals	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	Physicians Total Care, Inc.	2004-05-18	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Eon Labs, Inc.	2004-04-23	Not applicable	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	bryant ranch prepack	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	20 1/1	Oral	Cipla Limited	2016-06-16	Not applicable	US
Fosinopril Sodium	Tablet	10 1/1	Oral	A S Medication Solutions	2016-06-16	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Aurobindo Pharma	2011-03-30	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2005-06-21	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2004-04-23	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Physicians Total Care, Inc.	2004-11-18	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	A S Medication Solutions	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	40 1/1	Oral	Cipla Limited	2016-06-16	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	bryant ranch prepack	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	St. Marys Medical Park Pharmacy	2014-04-21	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2004-04-23	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Dispensing Solutions, Inc.	2004-04-23	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2005-06-21	Not applicable	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	Teva	2003-12-01	Not applicable	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	Golden State Medical Supply	2011-12-27	Not applicable	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	A S Medication Solutions	2007-09-17	Not applicable	US
Fosinopril Sodium	Tablet	10 mg/1	Oral	A S Medication Solutions	2004-04-23	Not applicable	US
Fosinopril Sodium	Tablet	40 mg/1	Oral	St. Marys Medical Park Pharmacy	2014-05-22	Not applicable	US
Fosinopril Sodium	Tablet	20 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2004-04-23	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Acecor	SPA (Czech Republic)
Monopril	Bristol-Myers Squibb
Staril	BMS (United Kingdom)

Brand mixtures

Name	Labeller	Ingredients
Fosinopril Sodium and Hydrochlorothiazide	Heritage	Fosinopril Hydrochlorothiazide

Categories

UNII

R43D2573WO

CAS number

98048-97-6

Weight

Average: 563.6625
Monoisotopic: 563.301189343

Chemical Formula

C₃₀H₄₆NO₇P

InChI Key

BIDNLKIUORFRQP-FKDWWROVSA-N

InChI

InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1

IUPAC Name

(2S,4S)-4-cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid

SMILES

CCC(=O)OC(OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[[email protected]]1C(O)=O)C1CCCCC1)C(C)C

Pharmacology

Indication

For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Structured Indications

Pharmacodynamics

Following oral administration, fosinopril is rapidly and completely hydrolyzed to its principle active metabolite, fosinoprilat. Hydrolysis is thought to occur in the gastrointestinal mucosa and liver. Fosinoprilat is a competitive inhibitor of ACE, a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of fosinoprilat by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Fosinoprilat, the active metabolite of fosinopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Fosinoprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Angiotensin-converting enzyme	Protein	yes	inhibitor	Human	P12821	details

Absorption

Average absolute absorption is 36%. The primary site of absorption is the proximal small intestine (duodenum/jejunum). Food slows the rate of absorption with no effect on the extent of absorption.

Volume of distribution

Not Available

Protein binding

Fosinoprilat is ≥95% protein bound

Metabolism

Since fosinoprilat is not biotransformed after intravenous administration, fosinopril, not fosinoprilat, appears to be the precursor for the glucuronide and p-hydroxy metabolites.

Substrate	Enzymes	Product
Fosinopril	Not Available	Fosinoprilat	Details

Route of elimination

After oral administration of radiolabeled fosinopril, approximately half of the absorbed dose is excreted in the urine and the remainder is excreted in the feces.

Half life

12 hours

Clearance

26 - 39 mL/min [healthy]

Toxicity

Human overdoses of fosinopril have not been reported, but the most common manifestation of human fosinopril overdosage is likely to be hypotension. Oral doses of fosinopril at 2600 mg/kg in rats were associated with significant lethality. The most common adverse effects include dizzines, cough, fatigue, and headache.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category	SMPDB ID
Fosinopril Action Pathway	Drug action	SMP00149
Fosinopril Metabolism Pathway	Drug metabolism	SMP00594

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Fosinopril.	Experimental
Abacavir	The serum concentration of Abacavir can be decreased when it is combined with Fosinopril.	Approved, Investigational
Acebutolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Acebutolol.	Approved
Aceclofenac	The risk or severity of adverse effects can be increased when Fosinopril is combined with Aceclofenac.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Acetazolamide.	Approved, Vet Approved
Acetylsalicylic acid	Acetylsalicylic acid may decrease the antihypertensive activities of Fosinopril.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Fosinopril is combined with Adapalene.	Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.	Approved
Alfuzosin	The serum concentration of Alfuzosin can be increased when it is combined with Fosinopril.	Approved, Investigational
Aliskiren	Aliskiren may increase the hyperkalemic activities of Fosinopril.	Approved, Investigational
Allopurinol	The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Fosinopril.	Approved
Alogliptin	The risk or severity of adverse effects can be increased when Alogliptin is combined with Fosinopril.	Approved
Alprazolam	The serum concentration of Alprazolam can be increased when it is combined with Fosinopril.	Approved, Illicit, Investigational
Alprenolol	Fosinopril may increase the hypotensive activities of Alprenolol.	Approved, Withdrawn
Aluminum hydroxide	The serum concentration of Fosinopril can be decreased when it is combined with Aluminum hydroxide.	Approved
Ambrisentan	Fosinopril may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Fosinopril.	Experimental
Amifostine	Fosinopril may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Fosinopril is combined with Amiloride.	Approved
Amineptine	The serum concentration of Amineptine can be increased when it is combined with Fosinopril.	Illicit, Withdrawn
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Fosinopril.	Approved
Aminosalicylic Acid	Aminosalicylic Acid may decrease the antihypertensive activities of Fosinopril.	Approved
Amiodarone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be increased when it is combined with Fosinopril.	Approved
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Fosinopril.	Approved
Amobarbital	Amobarbital may increase the hypotensive activities of Fosinopril.	Approved, Illicit
Amphotericin B	The risk or severity of adverse effects can be increased when Fosinopril is combined with Amphotericin B.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Fosinopril is combined with Amyl Nitrite.	Approved
Andrographolide	The risk or severity of adverse effects can be increased when Fosinopril is combined with HMPL-004.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Antipyrine.	Approved
Apomorphine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Apomorphine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Apraclonidine.	Approved
Apremilast	The risk or severity of adverse effects can be increased when Fosinopril is combined with Apremilast.	Approved, Investigational
Aprotinin	Aprotinin may decrease the antihypertensive activities of Fosinopril.	Approved, Withdrawn
Ardeparin	Ardeparin may increase the hyperkalemic activities of Fosinopril.	Approved, Withdrawn
Aripiprazole	Aripiprazole may increase the hypotensive activities of Fosinopril.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Arotinolol.	Approved
Arsenic trioxide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Arsenic trioxide.	Approved, Investigational
Atenolol	The risk or severity of adverse effects can be increased when Atenolol is combined with Fosinopril.	Approved
Atorvastatin	The serum concentration of Atorvastatin can be increased when it is combined with Fosinopril.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Azapropazone.	Withdrawn
Azathioprine	Fosinopril may increase the myelosuppressive activities of Azathioprine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Azelastine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fosinopril.	Approved
Balsalazide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Balsalazide.	Approved, Investigational
Barbexaclone	Barbexaclone may increase the hypotensive activities of Fosinopril.	Experimental
Barbital	Barbital may increase the hypotensive activities of Fosinopril.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Barnidipine.	Approved
Bemiparin	Bemiparin may increase the hyperkalemic activities of Fosinopril.	Approved
Benazepril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Benazepril.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Fosinopril.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Fosinopril.	Withdrawn
Benoxaprofen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Benoxaprofen.	Withdrawn
Bepridil	Fosinopril may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Betaxolol	The risk or severity of adverse effects can be increased when Betaxolol is combined with Fosinopril.	Approved
Bethanidine	Bethanidine may increase the hypotensive activities of Fosinopril.	Approved
Betulinic Acid	The risk or severity of adverse effects can be increased when Fosinopril is combined with Betulinic Acid.	Investigational
Bimatoprost	Fosinopril may increase the hypotensive activities of Bimatoprost.	Approved, Investigational
Bismuth Subcitrate	The serum concentration of Fosinopril can be decreased when it is combined with Bismuth Subcitrate.	Approved
Bisoprolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Bisoprolol.	Approved
Boceprevir	The serum concentration of Fosinopril can be decreased when it is combined with Boceprevir.	Approved, Investigational
Bortezomib	The risk or severity of adverse effects can be increased when Fosinopril is combined with Bortezomib.	Approved, Investigational
Bosentan	Fosinopril may increase the hypotensive activities of Bosentan.	Approved, Investigational
Bretylium	The risk or severity of adverse effects can be increased when Fosinopril is combined with Bretylium.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Brimonidine is combined with Fosinopril.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Fosinopril.	Approved
Bromfenac	The risk or severity of adverse effects can be increased when Fosinopril is combined with Bromfenac.	Approved
Bromocriptine	The serum concentration of Bromocriptine can be increased when it is combined with Fosinopril.	Approved, Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Bupivacaine.	Approved, Investigational
Bupranolol	Fosinopril may increase the hypotensive activities of Bupranolol.	Approved
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Fosinopril.	Approved
Calcium carbonate	The serum concentration of Fosinopril can be decreased when it is combined with Calcium carbonate.	Approved
Canagliflozin	Canagliflozin may increase the hyperkalemic activities of Fosinopril.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Fosinopril.	Approved
Candoxatril	Fosinopril may increase the hypotensive activities of Candoxatril.	Experimental
Captopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Captopril.	Approved
Carbamazepine	The metabolism of Fosinopril can be increased when combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Carbetocin.	Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Fosinopril.	Withdrawn
Carprofen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Carprofen.	Approved, Vet Approved, Withdrawn
Carteolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Carteolol.	Approved
Carvedilol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Castanospermine.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Fosinopril is combined with Celecoxib.	Approved, Investigational
Celiprolol	Fosinopril may increase the hypotensive activities of Celiprolol.	Approved, Investigational
Certoparin	Certoparin may increase the hyperkalemic activities of Fosinopril.	Approved
Chloroquine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Chloroquine.	Approved, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Chlorothiazide.	Approved, Vet Approved
Chlorotrianisene	The serum concentration of Chlorotrianisene can be decreased when it is combined with Fosinopril.	Withdrawn
Chlorpromazine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Chlorpromazine.	Approved, Vet Approved
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Fosinopril.	Approved
Cilazapril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Cilnidipine.	Approved
Ciprofloxacin	Fosinopril may increase the arrhythmogenic activities of Ciprofloxacin.	Approved, Investigational
Cisapride	The serum concentration of Cisapride can be increased when it is combined with Fosinopril.	Approved, Investigational, Withdrawn
Clarithromycin	The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Fosinopril.	Approved
Clevidipine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.	Approved
Clofarabine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Clofarabine.	Approved, Investigational
Clomipramine	The serum concentration of Clomipramine can be increased when it is combined with Fosinopril.	Approved, Vet Approved
Clonidine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Clonidine.	Approved
Clonixin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Clonixin.	Approved
Clozapine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Clozapine.	Approved
Conivaptan	The risk or severity of adverse effects can be increased when Fosinopril is combined with Conivaptan.	Approved, Investigational
Conjugated Equine Estrogens	The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Fosinopril.	Approved
Cryptenamine	Fosinopril may increase the hypotensive activities of Cryptenamine.	Approved
Cyclobenzaprine	The serum concentration of Cyclobenzaprine can be increased when it is combined with Fosinopril.	Approved
Cyclophosphamide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The serum concentration of Cyclosporine can be increased when it is combined with Fosinopril.	Approved, Investigational, Vet Approved
Cyclothiazide	Fosinopril may increase the hypotensive activities of Cyclothiazide.	Approved
Dalteparin	Dalteparin may increase the hyperkalemic activities of Fosinopril.	Approved
Dapagliflozin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Dapagliflozin.	Approved
Dapoxetine	Dapoxetine may increase the orthostatic hypotensive activities of Fosinopril.	Investigational
Debrisoquin	Fosinopril may increase the hypotensive activities of Debrisoquin.	Approved
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Fosinopril.	Approved
Deserpidine	Fosinopril may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Fosinopril is combined with Desflurane.	Approved
Desipramine	The serum concentration of Desipramine can be increased when it is combined with Fosinopril.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Dexmedetomidine.	Approved, Vet Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Fosinopril.	Approved
Diclofenac	The risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenac.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenamide.	Approved
Dienestrol	The serum concentration of Dienestrol can be decreased when it is combined with Fosinopril.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Fosinopril.	Approved
Diflunisal	Diflunisal may decrease the antihypertensive activities of Fosinopril.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Fosinopril.	Approved
Dihydroergotamine	The serum concentration of Dihydroergotamine can be increased when it is combined with Fosinopril.	Approved
Diltiazem	The metabolism of Diltiazem can be decreased when combined with Fosinopril.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Fosinopril is combined with Dinutuximab.	Approved
Dipyridamole	The risk or severity of adverse effects can be increased when Fosinopril is combined with Dipyridamole.	Approved
Dorzolamide	Fosinopril may increase the hypotensive activities of Dorzolamide.	Approved
Dosulepin	The serum concentration of Dosulepin can be increased when it is combined with Fosinopril.	Approved
Doxazosin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Doxepin can be increased when it is combined with Fosinopril.	Approved
Drospirenone	Fosinopril may increase the hyperkalemic activities of Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Fosinopril is combined with Droxicam.	Approved
Duloxetine	Fosinopril may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Dyphylline	The serum concentration of Dyphylline can be decreased when it is combined with Fosinopril.	Approved
Efonidipine	Fosinopril may increase the hypotensive activities of Efonidipine.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Empagliflozin.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	Fosinopril may increase the hypotensive activities of Enalaprilat.	Approved
Enfuvirtide	The serum concentration of Enfuvirtide can be increased when it is combined with Fosinopril.	Approved, Investigational
Enoxaparin	Enoxaparin may increase the hyperkalemic activities of Fosinopril.	Approved
Epirizole	The risk or severity of adverse effects can be increased when Fosinopril is combined with Epirizole.	Approved
Eplerenone	Eplerenone may increase the hyperkalemic activities of Fosinopril.	Approved
Epoprostenol	Fosinopril may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Fosinopril.	Approved
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be increased when it is combined with Fosinopril.	Approved
Ergonovine	The serum concentration of Ergonovine can be increased when it is combined with Fosinopril.	Approved
Ergotamine	The serum concentration of Ergotamine can be increased when it is combined with Fosinopril.	Approved
Esmirtazapine	The serum concentration of Esmirtazapine can be increased when it is combined with Fosinopril.	Investigational
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Fosinopril.	Approved
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Fosinopril.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Estramustine can be decreased when it is combined with Fosinopril.	Approved
Estrogens, esterified	The serum concentration of Estrogens, esterified can be decreased when it is combined with Fosinopril.	Approved
Estrone sulfate	The serum concentration of Estrone sulfate can be decreased when it is combined with Fosinopril.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Fosinopril is combined with Etacrynic acid.	Approved
Etanercept	The risk or severity of adverse effects can be increased when Fosinopril is combined with Etanercept.	Approved, Investigational
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Fosinopril.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Fosinopril is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Fosinopril is combined with Etofenamate.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Fosinopril is combined with Etoricoxib.	Approved, Investigational
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Fosinopril.	Approved
Everolimus	The risk or severity of adverse effects can be increased when Everolimus is combined with Fosinopril.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Felodipine.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Fenbufen.	Approved
Fenoldopam	Fosinopril may increase the hypotensive activities of Fenoldopam.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Fenoprofen.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Fosinopril is combined with Fimasartan.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Floctafenine.	Approved, Withdrawn
Flurbiprofen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Flurbiprofen.	Approved, Investigational
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Fosinopril.	Experimental
Furazolidone	Furazolidone may increase the hypotensive activities of Fosinopril.	Approved, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Furosemide.	Approved, Vet Approved
Guanabenz	Fosinopril may increase the hypotensive activities of Guanabenz.	Approved
Guanadrel	Guanadrel may increase the hypotensive activities of Fosinopril.	Approved
Guanethidine	Fosinopril may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Guanfacine.	Approved, Investigational
Halothane	The risk or severity of adverse effects can be increased when Fosinopril is combined with Halothane.	Approved, Vet Approved
Heparin	Heparin may increase the hyperkalemic activities of Fosinopril.	Approved, Investigational
Hexamethonium	Fosinopril may increase the hypotensive activities of Hexamethonium.	Experimental
Hexestrol	The serum concentration of Hexestrol can be decreased when it is combined with Fosinopril.	Withdrawn
Hexobarbital	Hexobarbital may increase the hypotensive activities of Fosinopril.	Approved
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Fosinopril.	Approved
Hydralazine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydroflumethiazide	Fosinopril may increase the hypotensive activities of Hydroflumethiazide.	Approved
Ibuprofen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Ibuprofen.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Fosinopril is combined with Ibuproxam.	Withdrawn
Icatibant	Icatibant may decrease the antihypertensive activities of Fosinopril.	Approved
Iloprost	Iloprost may increase the hypotensive activities of Fosinopril.	Approved, Investigational
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Fosinopril.	Approved
Indapamide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Indapamide.	Approved
Indenolol	Fosinopril may increase the hypotensive activities of Indenolol.	Withdrawn
Indomethacin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Indomethacin.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Indoprofen.	Withdrawn
Indoramin	Fosinopril may increase the hypotensive activities of Indoramin.	Withdrawn
Iproclozide	Iproclozide may increase the hypotensive activities of Fosinopril.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Fosinopril.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Fosinopril.	Approved, Investigational
Iron	The risk or severity of adverse effects can be increased when Fosinopril is combined with Iron.	Approved
Iron Dextran	The risk or severity of adverse effects can be increased when Fosinopril is combined with Iron Dextran.	Approved, Vet Approved
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Fosinopril.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Fosinopril is combined with Isoflurane.	Approved, Vet Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Dinitrate.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Mononitrate.	Approved
Isoxicam	The risk or severity of adverse effects can be increased when Fosinopril is combined with Isoxicam.	Withdrawn
Isoxsuprine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Fosinopril.	Approved
Kebuzone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Kebuzone.	Experimental
Ketoprofen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Ketoprofen.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Fosinopril is combined with Ketorolac.	Approved
Labetalol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Labetalol.	Approved
Lacidipine	Fosinopril may increase the hypotensive activities of Lacidipine.	Approved
Lanthanum carbonate	The serum concentration of Fosinopril can be decreased when it is combined with Lanthanum carbonate.	Approved
Latanoprost	Fosinopril may increase the hypotensive activities of Latanoprost.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Leflunomide.	Approved, Investigational
Lercanidipine	Fosinopril may increase the hypotensive activities of Lercanidipine.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Levobupivacaine.	Approved
Levodopa	Fosinopril may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Fosinopril is combined with Levosimendan.	Approved, Investigational
Linagliptin	The risk or severity of adverse effects can be increased when Linagliptin is combined with Fosinopril.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Lisinopril.	Approved, Investigational
Lithium	The serum concentration of Lithium can be increased when it is combined with Fosinopril.	Approved
Lofexidine	Fosinopril may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Lornoxicam	The risk or severity of adverse effects can be increased when Fosinopril is combined with Lornoxicam.	Approved
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Fosinopril.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Fosinopril.	Approved, Investigational
Loxoprofen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Loxoprofen.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Fosinopril is combined with Lumiracoxib.	Approved, Investigational
Macitentan	Fosinopril may increase the hypotensive activities of Macitentan.	Approved
Magaldrate	The serum concentration of Fosinopril can be decreased when it is combined with Magaldrate.	Withdrawn
Magnesium carbonate	The serum concentration of Fosinopril can be decreased when it is combined with Magnesium carbonate.	Approved
Magnesium Hydroxide	The serum concentration of Fosinopril can be decreased when it is combined with Magnesium hydroxide.	Approved
Magnesium oxide	The serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide.	Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Fosinopril is combined with Magnesium salicylate.	Approved
Magnesium Trisilicate	The serum concentration of Fosinopril can be decreased when it is combined with Magnesium Trisilicate.	Approved
Manidipine	Fosinopril may increase the hypotensive activities of Manidipine.	Approved
Mannitol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Mannitol.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Masoprocol.	Approved
Mebanazine	Mebanazine may increase the hypotensive activities of Fosinopril.	Withdrawn
Mecamylamine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Mecamylamine.	Approved
Meclofenamic acid	The risk or severity of adverse effects can be increased when Fosinopril is combined with Meclofenamic acid.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Fosinopril is combined with Mefenamic acid.	Approved
Meloxicam	The risk or severity of adverse effects can be increased when Fosinopril is combined with Meloxicam.	Approved, Vet Approved
Mesalazine	Mesalazine may decrease the antihypertensive activities of Fosinopril.	Approved
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Fosinopril.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Fosinopril is combined with Metamizole.	Withdrawn
Methallenestril	The serum concentration of Methallenestril can be decreased when it is combined with Fosinopril.	Experimental
Methazolamide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Methazolamide.	Approved
Methohexital	Methohexital may increase the hypotensive activities of Fosinopril.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Fosinopril.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Fosinopril is combined with Methyldopa.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Fosinopril.	Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Fosinopril.	Approved, Investigational
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Fosinopril.	Approved
Metipranolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Metipranolol.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Metolazone.	Approved
Metoprolol	The risk or severity of adverse effects can be increased when Metoprolol is combined with Fosinopril.	Approved, Investigational
Metyrosine	Fosinopril may increase the hypotensive activities of Metyrosine.	Approved
Mibefradil	Fosinopril may increase the hypotensive activities of Mibefradil.	Withdrawn
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Fosinopril.	Approved, Illicit
Minaprine	Minaprine may increase the hypotensive activities of Fosinopril.	Approved
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Fosinopril.	Approved
Mirtazapine	The serum concentration of Mirtazapine can be increased when it is combined with Fosinopril.	Approved
Moclobemide	Moclobemide may increase the hypotensive activities of Fosinopril.	Approved
Moexipril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Moexipril.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Fosinopril.	Approved
Morphine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Morphine.	Approved, Investigational
Moxonidine	Fosinopril may increase the hypotensive activities of Moxonidine.	Approved
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolate mofetil.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolic acid.	Approved
Nabilone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nabilone.	Approved, Investigational
Nabumetone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nabumetone.	Approved
Nadolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nadolol.	Approved
Nadroparin	Nadroparin may increase the hyperkalemic activities of Fosinopril.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nafamostat.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Naftifine.	Approved
Naproxen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Naproxen.	Approved, Vet Approved
NCX 4016	The risk or severity of adverse effects can be increased when Fosinopril is combined with NCX 4016.	Investigational
Nebivolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nebivolol.	Approved, Investigational
Nefazodone	The serum concentration of Nefazodone can be increased when it is combined with Fosinopril.	Approved, Withdrawn
Nepafenac	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nepafenac.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nesiritide.	Approved, Investigational
Nialamide	Nialamide may increase the hypotensive activities of Fosinopril.	Withdrawn
Nicardipine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nicardipine.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Fosinopril.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nifedipine.	Approved
Niflumic Acid	The risk or severity of adverse effects can be increased when Fosinopril is combined with Niflumic Acid.	Approved
Niguldipine	Fosinopril may increase the hypotensive activities of Niguldipine.	Experimental
Nilvadipine	Fosinopril may increase the hypotensive activities of Nilvadipine.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nimesulide.	Approved, Withdrawn
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Fosinopril.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Fosinopril.	Approved
Nitrendipine	Fosinopril may increase the hypotensive activities of Nitrendipine.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nitric Oxide.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Nitroglycerin.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Nitroprusside is combined with Fosinopril.	Approved
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Fosinopril.	Approved
Obinutuzumab	Fosinopril may increase the hypotensive activities of Obinutuzumab.	Approved
Octamoxin	Octamoxin may increase the hypotensive activities of Fosinopril.	Withdrawn
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Fosinopril.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Olopatadine.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Olsalazine.	Approved
Omapatrilat	Fosinopril may increase the hypotensive activities of Omapatrilat.	Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Oxaprozin.	Approved
Oxprenolol	Fosinopril may increase the hypotensive activities of Oxprenolol.	Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Oxyphenbutazone.	Withdrawn
Paclitaxel	The risk or severity of adverse effects can be increased when Fosinopril is combined with Paclitaxel.	Approved, Vet Approved
Papaverine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Papaverine.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Fosinopril is combined with Parecoxib.	Approved
Pargyline	Pargyline may increase the hypotensive activities of Fosinopril.	Approved
Parnaparin	Parnaparin may increase the hyperkalemic activities of Fosinopril.	Approved
Penbutolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Penbutolol.	Approved, Investigational
Pentobarbital	Pentobarbital may increase the hypotensive activities of Fosinopril.	Approved, Vet Approved
Pentolinium	Fosinopril may increase the hypotensive activities of Pentolinium.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Fosinopril.	Approved, Investigational
Perindopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Perindopril.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Pethidine.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Fosinopril.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Fosinopril.	Withdrawn
Phenobarbital	Phenobarbital may increase the hypotensive activities of Fosinopril.	Approved
Phenoxybenzamine	Fosinopril may increase the hypotensive activities of Phenoxybenzamine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Fosinopril.	Withdrawn
Phentolamine	Fosinopril may increase the hypotensive activities of Phentolamine.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Phenylbutazone.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Fosinopril is combined with Pimecrolimus.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be increased when it is combined with Fosinopril.	Approved
Pindolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Pindolol.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Pipamperone.	Approved
Piretanide	Piretanide may increase the hypotensive activities of Fosinopril.	Experimental
Pirfenidone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Pirfenidone.	Investigational
Pirlindole	Pirlindole may increase the hypotensive activities of Fosinopril.	Approved
Piroxicam	The risk or severity of adverse effects can be increased when Fosinopril is combined with Piroxicam.	Approved, Investigational
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Fosinopril.	Withdrawn
Polythiazide	Fosinopril may increase the hypotensive activities of Polythiazide.	Approved
Pramipexole	The risk or severity of adverse effects can be increased when Fosinopril is combined with Pramipexole.	Approved, Investigational
Prazosin	The risk or severity of adverse effects can be increased when Prazosin is combined with Fosinopril.	Approved
Pregabalin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Pregabalin.	Approved, Illicit, Investigational
Primidone	Primidone may increase the hypotensive activities of Fosinopril.	Approved, Vet Approved
Propacetamol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Propacetamol.	Approved
Propofol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Propofol.	Approved, Investigational, Vet Approved
Propranolol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Propranolol.	Approved, Investigational
Protriptyline	The serum concentration of Protriptyline can be increased when it is combined with Fosinopril.	Approved
PTC299	The risk or severity of adverse effects can be increased when Fosinopril is combined with PTC299.	Investigational
Quetiapine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Quetiapine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Quinapril.	Approved, Investigational
Quinethazone	Quinethazone may increase the hypotensive activities of Fosinopril.	Approved
Quinine	Quinine may increase the hypotensive activities of Fosinopril.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Fosinopril.	Approved
Rasagiline	Rasagiline may increase the hypotensive activities of Fosinopril.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Fosinopril is combined with Remifentanil.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Fosinopril.	Approved
Rescinnamine	Fosinopril may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Fosinopril.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Fosinopril is combined with Resveratrol.	Experimental, Investigational
Reviparin	Reviparin may increase the hyperkalemic activities of Fosinopril.	Approved
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Fosinopril.	Approved
Risperidone	Fosinopril may increase the hypotensive activities of Risperidone.	Approved, Investigational
Rituximab	Fosinopril may increase the hypotensive activities of Rituximab.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Fosinopril is combined with Rofecoxib.	Investigational, Withdrawn
Ropinirole	The risk or severity of adverse effects can be increased when Fosinopril is combined with Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Ropivacaine.	Approved
Rosuvastatin	The serum concentration of Rosuvastatin can be increased when it is combined with Fosinopril.	Approved
Rotigotine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Rotigotine.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Sacubitril.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Fosinopril.	Withdrawn
Salicylamide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Salicylamide.	Approved
Salicylic acid	Salicylic acid may decrease the antihypertensive activities of Fosinopril.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Fosinopril is combined with Salsalate.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Fosinopril.	Experimental
Saxagliptin	The risk or severity of adverse effects can be increased when Saxagliptin is combined with Fosinopril.	Approved
Secobarbital	Secobarbital may increase the hypotensive activities of Fosinopril.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Fosinopril.	Approved, Investigational, Vet Approved
Selexipag	Fosinopril may increase the hypotensive activities of Selexipag.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Fosinopril is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	The serum concentration of Sildenafil can be increased when it is combined with Fosinopril.	Approved, Investigational
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Fosinopril.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Fosinopril.	Approved
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Fosinopril.	Approved, Investigational
Sitagliptin	The risk or severity of adverse effects can be increased when Sitagliptin is combined with Fosinopril.	Approved, Investigational
Sitaxentan	Fosinopril may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sodium aurothiomalate	The risk or severity of adverse effects can be increased when Fosinopril is combined with Sodium aurothiomalate.	Approved
Sodium Nitrite	The risk or severity of adverse effects can be increased when Fosinopril is combined with Sodium Nitrite.	Approved
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Fosinopril.	Approved
Spirapril	Fosinopril may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Fosinopril.	Approved
SRT501	The risk or severity of adverse effects can be increased when Fosinopril is combined with SRT501.	Investigational
St. John's Wort	The metabolism of Fosinopril can be increased when combined with St. John's Wort.	Nutraceutical
Streptokinase	The risk or severity of adverse effects can be increased when Fosinopril is combined with Streptokinase.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Fosinopril is combined with Sufentanil.	Approved, Investigational
Sulfasalazine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Sulfasalazine.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Fosinopril is combined with Sulindac.	Approved
Suprofen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Suprofen.	Approved, Withdrawn
Synthetic Conjugated Estrogens, A	The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Fosinopril.	Approved
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Fosinopril.	Approved, Investigational
Tadalafil	Tadalafil may increase the antihypertensive activities of Fosinopril.	Approved, Investigational
Tamsulosin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Tamsulosin.	Approved, Investigational
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Fosinopril.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Fosinopril.	Approved, Investigational
Temocapril	Fosinopril may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Fosinopril is combined with Temsirolimus.	Approved
Tenoxicam	The risk or severity of adverse effects can be increased when Fosinopril is combined with Tenoxicam.	Approved
Terazosin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Terazosin.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Teriflunomide.	Approved
Terlipressin	Fosinopril may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Fosinopril is combined with Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Fosinopril.	Approved
Thiamylal	Thiamylal may increase the hypotensive activities of Fosinopril.	Approved, Vet Approved
Thiopental	Thiopental may increase the hypotensive activities of Fosinopril.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Fosinopril is combined with Thioridazine.	Withdrawn
Tianeptine	The serum concentration of Tianeptine can be increased when it is combined with Fosinopril.	Approved
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Fosinopril is combined with Tiaprofenic acid.	Approved
Tibolone	Fosinopril may increase the hypotensive activities of Tibolone.	Approved
Ticrynafen	Fosinopril may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	The risk or severity of adverse effects can be increased when Timolol is combined with Fosinopril.	Approved
Tinzaparin	Tinzaparin may increase the hyperkalemic activities of Fosinopril.	Approved
Tipranavir	The serum concentration of Fosinopril can be decreased when it is combined with Tipranavir.	Approved, Investigational
Tizanidine	Tizanidine may increase the hypotensive activities of Fosinopril.	Approved
Tolazoline	Fosinopril may increase the hypotensive activities of Tolazoline.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Fosinopril is combined with Tolcapone.	Approved, Withdrawn
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Fosinopril is combined with Tolfenamic Acid.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Tolmetin.	Approved
Toloxatone	Toloxatone may increase the hypotensive activities of Fosinopril.	Approved
Tolvaptan	Tolvaptan may increase the hyperkalemic activities of Fosinopril.	Approved
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Fosinopril.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Trandolapril.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Fosinopril is combined with Tranilast.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fosinopril.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Fosinopril.	Approved
Travoprost	Travoprost may increase the hypotensive activities of Fosinopril.	Approved
Treprostinil	Treprostinil may increase the hypotensive activities of Fosinopril.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Fosinopril is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Fosinopril.	Approved
Triazolam	The serum concentration of Triazolam can be increased when it is combined with Fosinopril.	Approved
Trichlormethiazide	Fosinopril may increase the hypotensive activities of Trichlormethiazide.	Approved, Vet Approved
Trimazosin	Fosinopril may increase the hypotensive activities of Trimazosin.	Experimental
Trimethaphan	Fosinopril may increase the hypotensive activities of Trimethaphan.	Approved
Trimethoprim	Trimethoprim may increase the hyperkalemic activities of Fosinopril.	Approved, Vet Approved
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Fosinopril.	Approved
Trisalicylate-choline	The risk or severity of adverse effects can be increased when Fosinopril is combined with Trisalicylate-choline.	Approved
Udenafil	Udenafil may increase the antihypertensive activities of Fosinopril.	Approved, Investigational
Unoprostone	Fosinopril may increase the hypotensive activities of Unoprostone.	Approved
Valdecoxib	The risk or severity of adverse effects can be increased when Fosinopril is combined with Valdecoxib.	Investigational, Withdrawn
Valproic Acid	The serum concentration of Valproic Acid can be decreased when it is combined with Fosinopril.	Approved, Investigational
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Fosinopril.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Fosinopril.	Approved
Verapamil	The metabolism of Verapamil can be decreased when combined with Fosinopril.	Approved
Vildagliptin	The risk or severity of adverse effects can be increased when Vildagliptin is combined with Fosinopril.	Approved, Investigational
Xylometazoline	Fosinopril may increase the hypotensive activities of Xylometazoline.	Approved
Yohimbine	Yohimbine may decrease the antihypertensive activities of Fosinopril.	Approved, Vet Approved
Zaltoprofen	The risk or severity of adverse effects can be increased when Fosinopril is combined with Zaltoprofen.	Approved
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Fosinopril.	Approved
Zileuton	The risk or severity of adverse effects can be increased when Fosinopril is combined with Zileuton.	Approved, Investigational, Withdrawn
Zomepirac	The risk or severity of adverse effects can be increased when Fosinopril is combined with Zomepirac.	Withdrawn

Food Interactions

Do not take calcium, aluminum, magnesium or iron supplements, or antacids within 2 hours of taking this medication.
Fosinopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
Herbs that may attenuate the antihypertensive effect of fosinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
High salt intake may attenuate the antihypertensive effect of fosinopril.
Take without regard to meals.

References

Synthesis Reference

Sandra Gallego Pato, Antonio Palomo Coll, Francisco Palomo Nicolau, "Preparation of crystalline polymorphs of fosinopril sodium." U.S. Patent US20050010054, issued January 13, 2005.

US20050010054

General References

David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ: A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813. [PubMed:11854791 ]
Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14635
KEGG Drug	D00622
KEGG Compound	C07016
PubChem Compound	55891
PubChem Substance	46506495
ChemSpider	50469
ChEBI	5163
ChEMBL	CHEMBL3306578
Therapeutic Targets Database	DAP000582
PharmGKB	PA449710
Drug Product Database	1744
RxList	http://www.rxlist.com/cgi/generic/fosinop.htm
Drugs.com	http://www.drugs.com/cdi/fosinopril.html
PDRhealth	http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=Mon1274.html&contentName=Monopril&contentId=
Wikipedia	Fosinopril

ATC Codes

C09AA09

C09BA09

AHFS Codes

24:32.04

PDB Entries

1UZF

FDA label

Download (206 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Completed	Prevention	Cardiovascular Disease (CVD) / Heart Diseases / Hypertensive	1
2	Completed	Treatment	Diabetic Nephropathies	1
3	Completed	Prevention	Cardiovascular Disease (CVD) / Microalbuminuria / Renal Diseases	1
4	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Completed	Treatment	Hypertensive	1
4	Not Yet Recruiting	Treatment	Chronic Kidney Disease (CKD)	1
Not Available	Completed	Not Available	Healthy Volunteers	4
Not Available	Completed	Treatment	Diabetes Mellitus (DM) / Hypertension,Essential	1
Not Available	Unknown Status	Treatment	Angiotensin II Type 1 Receptor Blockers / Angiotensin-Converting Enzyme Inhibitors / Chronic Kidney Insufficiency / Proteinuria	1

Pharmacoeconomics

Manufacturers

Apotex inc etobicoke site
Invagen pharmaceuticals inc
Ranbaxy laboratories ltd
Sandoz inc
Teva pharmaceuticals usa inc
Watson laboratories inc
Watson laboratories inc florida
Bristol myers squibb co pharmaceutical research institute

Packagers

Apotex Inc.
A-S Medication Solutions LLC
Atlantic Biologicals Corporation
Blu Pharmaceuticals LLC
Bristol-Myers Squibb Co.
Cobalt Pharmaceuticals Inc.
Deca Pharmaceuticals LLC
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Eon Labs
Glenmark Generics Ltd.
InvaGen Pharmaceuticals Inc.
Ivax Pharmaceuticals
Kaiser Foundation Hospital
Murfreesboro Pharmaceutical Nursing Supply
Neuman Distributors Inc.
Nucare Pharmaceuticals Inc.
Physicians Total Care Inc.
Prepackage Specialists
Prepak Systems Inc.
Princeton Pharmaceutical Products Inc.
Ranbaxy Laboratories
Resource Optimization and Innovation LLC
Teva Pharmaceutical Industries Ltd.
Va Cmop Dallas
Watson Pharmaceuticals

Dosage forms

Form	Route	Strength
Tablet	Oral	10 mg/1
Tablet	Oral	10 1/1
Tablet	Oral	20 1/1
Tablet	Oral	20 mg/1
Tablet	Oral	40 mg/1
Tablet	Oral	40 1/1
Tablet	Oral
Tablet	Oral	10 mg
Tablet	Oral	20 mg

Prices

Unit description	Cost	Unit
Monopril HCT 10-12.5 mg tablet	1.71USD	tablet
Monopril 10 mg tablet	1.68USD	tablet
Monopril 40 mg tablet	1.67USD	tablet
Monopril 20 mg tablet	1.62USD	tablet
Fosinopril Sodium-HCTZ 10-12.5 mg tablet	1.61USD	tablet
Fosinopril Sodium-HCTZ 20-12.5 mg tablet	1.61USD	tablet
Fosinopril sodium 20 mg tablet	1.25USD	tablet
Fosinopril sodium 40 mg tablet	1.25USD	tablet
Fosinopril sodium 10 mg tablet	1.21USD	tablet
Monopril 20 mg Tablet	1.1USD	tablet
Monopril 10 mg Tablet	0.91USD	tablet
Apo-Fosinopril 20 mg Tablet	0.61USD	tablet
Fosinopril 20 mg Tablet	0.61USD	tablet
Jamp-Fosinopril 20 mg Tablet	0.61USD	tablet
Mylan-Fosinopril 20 mg Tablet	0.61USD	tablet
Novo-Fosinopril 20 mg Tablet	0.61USD	tablet
Ran-Fosinopril 20 mg Tablet	0.61USD	tablet
Apo-Fosinopril 10 mg Tablet	0.51USD	tablet
Fosinopril 10 mg Tablet	0.51USD	tablet
Jamp-Fosinopril 10 mg Tablet	0.51USD	tablet
Mylan-Fosinopril 10 mg Tablet	0.51USD	tablet
Novo-Fosinopril 10 mg Tablet	0.51USD	tablet
Ran-Fosinopril 10 mg Tablet	0.51USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5006344	No	1993-01-10	2010-01-10	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	149-153 °C	Not Available
water solubility	Insoluble	Not Available
logP	6.3	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00101 mg/mL	ALOGPS
logP	4.71	ALOGPS
logP	5.49	ChemAxon
logS	-5.8	ALOGPS
pKa (Strongest Acidic)	3.87	ChemAxon
pKa (Strongest Basic)	-4.4	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	110.21 Å²	ChemAxon
Rotatable Bond Count	15	ChemAxon
Refractivity	149.12 m³·mol^-1	ChemAxon
Polarizability	61.17 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9532
Blood Brain Barrier	-	0.667
Caco-2 permeable	-	0.6561
P-glycoprotein substrate	Substrate	0.6165
P-glycoprotein inhibitor I	Inhibitor	0.7161
P-glycoprotein inhibitor II	Non-inhibitor	0.6774
Renal organic cation transporter	Non-inhibitor	0.812
CYP450 2C9 substrate	Non-substrate	0.7028
CYP450 2D6 substrate	Non-substrate	0.8128
CYP450 3A4 substrate	Substrate	0.6729
CYP450 1A2 substrate	Non-inhibitor	0.8913
CYP450 2C9 inhibitor	Non-inhibitor	0.7438
CYP450 2D6 inhibitor	Non-inhibitor	0.9004
CYP450 2C19 inhibitor	Non-inhibitor	0.5725
CYP450 3A4 inhibitor	Non-inhibitor	0.7303
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.6376
Ames test	Non AMES toxic	0.7141
Carcinogenicity	Non-carcinogens	0.8025
Biodegradation	Not ready biodegradable	0.8102
Rat acute toxicity	2.8211 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9534
hERG inhibition (predictor II)	Non-inhibitor	0.5918

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , negative	splash10-014i-0000900000-f61a6a8a62cc0c92102b	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , negative	splash10-014i-0000900000-ed280398ec57e4a02dce	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , negative	splash10-00di-0090300000-4e1c300644a39a64aefe	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , negative	splash10-00di-0090000000-85f8c80f83290feea35c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , negative	splash10-00di-0090000000-e28a43e299ff58e3a6bc	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-014i-0010900000-a142ed389f6652d197f1	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-00di-1090000000-833fa43a37b31e08737c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-00di-1090000000-cda46913f10b57e39204	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-00di-2290000000-8627963d14d5d091e338	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0229-7890000000-a5186e8ef5fa038d0a91	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-03k9-9720000000-ff0242177e3d4ef6c38a	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-000f-0000900000-a2e65cd39ca7266f3a02	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-000i-0000900000-0eee13fe1a605e98c985	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-00ku-0105900000-1253dd1cea86dcfde7f6	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0udl-0908200000-59ff4955c6e6b2d36435	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0udi-0901000000-e2b0d1bb8bfd4d6f7595	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-000i-0000900000-f625a00c8eb75cbf317d	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0f6x-0409200000-5a18b8096c457898aa5f	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0udi-0900000000-28e69824d7a0442561b6	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Proline and derivatives

Alternative Parents

N-acyl-L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Phosphinic acid esters / Carboxylic acid esters / Carboxylic acids / Azacyclic compounds

Substituents

N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Proline or derivatives / N-acylpyrrolidine / Pyrrolidine carboxylic acid / Pyrrolidine carboxylic acid or derivatives / Dicarboxylic acid or derivatives / Monocyclic benzene moiety / Benzenoid

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

L-proline derivative, phosphinic ester (CHEBI:5163 )

Targets

Details

1. Angiotensin-converting enzyme

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Zinc ion binding
Specific Function:: Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:: ACE
Uniprot ID:: P12821
Molecular Weight:: 149713.675 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Ondetti MA: Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation. 1988 Jun;77(6 Pt 2):I74-8. [PubMed:2836111 ]
Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095 ]

Transporters

Details

1. Solute carrier family 15 member 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:: Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:: SLC15A1
Uniprot ID:: P46059
Molecular Weight:: 78805.265 Da

References

Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]

Details

2. Solute carrier family 15 member 2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Peptide:proton symporter activity
Specific Function:: Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:: SLC15A2
Uniprot ID:: Q16348
Molecular Weight:: 81782.77 Da

References

Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]

Drug created on June 13, 2005 07:24 / Updated on June 11, 2017 15:38

Get DrugBank to go!

Structure for DB00492 (Fosinopril)

Targets

References

Transporters

References

References